CA3039199A1 - Apilimod compositions and methods for using same in the treatment of alzheimer's disease - Google Patents
Apilimod compositions and methods for using same in the treatment of alzheimer's disease Download PDFInfo
- Publication number
- CA3039199A1 CA3039199A1 CA3039199A CA3039199A CA3039199A1 CA 3039199 A1 CA3039199 A1 CA 3039199A1 CA 3039199 A CA3039199 A CA 3039199A CA 3039199 A CA3039199 A CA 3039199A CA 3039199 A1 CA3039199 A1 CA 3039199A1
- Authority
- CA
- Canada
- Prior art keywords
- apilimod
- disease
- alzheimer
- subject
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407186P | 2016-10-12 | 2016-10-12 | |
| US62/407,186 | 2016-10-12 | ||
| PCT/US2017/056147 WO2018071548A1 (en) | 2016-10-12 | 2017-10-11 | Apilimod compositions and methods for using same in the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3039199A1 true CA3039199A1 (en) | 2018-04-19 |
Family
ID=60268450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3039199A Pending CA3039199A1 (en) | 2016-10-12 | 2017-10-11 | Apilimod compositions and methods for using same in the treatment of alzheimer's disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190365771A1 (https=) |
| EP (1) | EP3525794A1 (https=) |
| JP (1) | JP7199349B2 (https=) |
| KR (1) | KR20190067824A (https=) |
| CN (1) | CN110167559A (https=) |
| AU (1) | AU2017342262B2 (https=) |
| BR (1) | BR112019007214A2 (https=) |
| CA (1) | CA3039199A1 (https=) |
| IL (1) | IL265911A (https=) |
| MX (1) | MX2019004179A (https=) |
| RU (1) | RU2019113752A (https=) |
| WO (1) | WO2018071548A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12589097B2 (en) | 2018-02-21 | 2026-03-31 | OrphAl Therapeutics Inc. | Apilimod compositions and methods of use |
| AU2019223014B2 (en) | 2018-02-21 | 2024-10-17 | Orphai Therapeutics Inc. | Combination therapy with apilimod and glutamatergic agents |
| CN116059192B (zh) | 2019-11-13 | 2024-10-29 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7923557B2 (en) | 2004-11-10 | 2011-04-12 | Synta Pharmaceuticals Corporation | Process for preparing trisubstituted pyrimidine compounds |
| US7863270B2 (en) | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| US20130302343A1 (en) | 2011-01-04 | 2013-11-14 | Charité Universitätsmedizin Berlin | Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease |
| US10206910B2 (en) * | 2014-11-07 | 2019-02-19 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
| CA2966334A1 (en) * | 2014-11-07 | 2016-05-12 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of colorectal cancer |
| US10729694B2 (en) * | 2015-01-23 | 2020-08-04 | AI Therapeutics, Inc. | Anti-viral compositions containing PIKfyve inhibitors and use thereof |
| US20180015098A1 (en) * | 2015-02-03 | 2018-01-18 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| US10758545B2 (en) * | 2015-06-25 | 2020-09-01 | University Of Southern California | Methods to treat neurological diseases |
-
2017
- 2017-10-11 KR KR1020197012287A patent/KR20190067824A/ko not_active Ceased
- 2017-10-11 CA CA3039199A patent/CA3039199A1/en active Pending
- 2017-10-11 RU RU2019113752A patent/RU2019113752A/ru not_active Application Discontinuation
- 2017-10-11 WO PCT/US2017/056147 patent/WO2018071548A1/en not_active Ceased
- 2017-10-11 BR BR112019007214A patent/BR112019007214A2/pt not_active Application Discontinuation
- 2017-10-11 US US16/340,845 patent/US20190365771A1/en not_active Abandoned
- 2017-10-11 CN CN201780076520.2A patent/CN110167559A/zh active Pending
- 2017-10-11 AU AU2017342262A patent/AU2017342262B2/en not_active Ceased
- 2017-10-11 EP EP17794818.9A patent/EP3525794A1/en not_active Withdrawn
- 2017-10-11 MX MX2019004179A patent/MX2019004179A/es unknown
- 2017-10-11 JP JP2019519652A patent/JP7199349B2/ja active Active
-
2019
- 2019-04-08 IL IL265911A patent/IL265911A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190067824A (ko) | 2019-06-17 |
| RU2019113752A (ru) | 2020-11-13 |
| WO2018071548A1 (en) | 2018-04-19 |
| AU2017342262A1 (en) | 2019-04-18 |
| US20190365771A1 (en) | 2019-12-05 |
| IL265911A (en) | 2019-06-30 |
| JP7199349B2 (ja) | 2023-01-05 |
| BR112019007214A2 (pt) | 2019-07-02 |
| RU2019113752A3 (https=) | 2021-01-19 |
| EP3525794A1 (en) | 2019-08-21 |
| MX2019004179A (es) | 2019-09-02 |
| AU2017342262B2 (en) | 2023-09-28 |
| CN110167559A (zh) | 2019-08-23 |
| JP2019530711A (ja) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11957688B2 (en) | Combination therapy with apilimod and glutamatergic agents | |
| US20160287605A1 (en) | Combination therapy | |
| CN107249638B (zh) | 阿匹莫德用于治疗肾癌 | |
| AU2015342876B2 (en) | Apilimod for use in the treatment of colorectal cancer | |
| US20200306255A1 (en) | Compositions and methods for treating niemann pick c disease | |
| AU2017342262B2 (en) | Apilimod compositions and methods for using same in the treatment of alzheimer's disease | |
| US12589097B2 (en) | Apilimod compositions and methods of use | |
| CA3090807C (en) | Combination therapy with apilimod and glutamatergic agents | |
| WO2025030033A1 (en) | Apilimod compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220915 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20241028 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251111 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251125 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260106 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260414 |